Arch Therapeutics is a medical device company developing a novel approach to stopping bleeding and controlling leaking during surgery and trauma care. The company’s leading product candidate, the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures, effectively making surgery faster and safer for patients. Unlike currently available products, AC5 has been shown to promptly stop bleeding by conforming to irregular wound geometry, and, with a completely transparent construction, it allows surgeons to maintain a clear field of vision directly into a wound without hampering future healing.
In recent months, Arch has made considerable progress in the development of its promising hemostatic device. In April, the company announced the results of a study designed to compare the effectiveness of AC5 against currently marketed hemostats. Arch’s device demonstrated an average time to hemostasis of significantly less than 30 seconds, while the commercially-available gelatin-thrombin hemostat took an average of more than 200 percent longer. In June, the company built on these results when it received favorable data from a preclinical toxicity test indicating that AC5 was well-tolerated among test subjects.
“These results present another snapshot of promising data for AC5,” Dr. Terrence Norchi, president and chief executive officer of Arch, stated in a news release. “We are continuing to study the characteristics, safety and performance of AC5 in preclinical studies as we prepare to start our human clinical trial next quarter.”
In an effort to fund its upcoming clinical studies, Arch recently completed a private placement that is expected to provide more than $3 million of additional capital after related expenses. With this added flexibility, the company will look to continue marching toward the eventual commercialization of AC5 following the completion of its impending human trials.
When commercialized, AC5 will give Arch improved access to the rapidly growth market for minimally invasive surgery (MIS). According to a report by Photonics, the global market for MIS is expected to reach $50.6 billion by 2019, up from just $25 billion in 2012. AC5 is ideal for this market because of it leaves no sticky or glue-like residue, enabling for improved precision during both MIS and open surgical procedures, as well as faster recovery times for patients.
Moving forward, Arch will continue toward the future commercialization of its innovative device. For prospective shareholders, this progress, along with the vast commercial potential of AC5 in a selection of thriving medical markets, makes the company an intriguing investment opportunity in the months to come.
For more information, visit www.archtherapeutics.com
